{"hands_on_practices": [{"introduction": "The most immediate obstacle in xenotransplantation is hyperacute rejection, a rapid and destructive immune response mediated by pre-existing antibodies. The intensity of this response is rooted in the biophysical properties of antibody-antigen binding, which can be quantified using the principles of chemical kinetics. This exercise [@problem_id:5076068] challenges you to calculate the equilibrium dissociation constant ($K_D$) for this critical interaction, providing a quantitative link between molecular affinity and the swift activation of the complement system that characterizes this profound immunological barrier.", "problem": "In a xenotransplantation setting, human serum containing natural antibodies encounters porcine endothelial cells expressing galactose-$\\alpha$-$1,3$-galactose (alpha-Gal). Consider the binding of an anti-alpha-Gal immunoglobulin to the alpha-Gal epitope on the endothelial surface under the law of mass action. Let $k_{\\text{on}}$ denote the second-order association rate constant for antibody-epitope binding, and $k_{\\text{off}}$ denote the first-order dissociation rate constant. Under equilibrium conditions, the equilibrium dissociation constant $K_D$ quantifies affinity and is defined by the ratio of free reactants to the bound complex.\n\nGiven $k_{\\text{on}}=10^{5}\\,\\text{M}^{-1}\\text{s}^{-1}$ and $k_{\\text{off}}=10^{-3}\\,\\text{s}^{-1}$ for the interaction of a representative human anti-alpha-Gal immunoglobulin with alpha-Gal on porcine endothelium, use mass-action kinetics and the equilibrium definition of $K_D$ to compute the equilibrium dissociation constant. Express your final answer in molar ($\\text{M}$). Do not perform any unit conversion. No rounding is required. Then, based on first principles of receptor-ligand occupancy and the requirements for activation of the classical pathway of complement (CP), reason qualitatively whether such binding kinetics are consistent with rapid complement activation on porcine endothelium upon exposure to human serum. Your final reported answer must be only the value of $K_D$ in $\\text{M}$ (without units in the box).", "solution": "The problem statement is evaluated for validity prior to attempting a solution.\n\n### Step 1: Extract Givens\n- **System:** Human serum containing natural antibodies encounters porcine endothelial cells expressing galactose-$\\alpha$-$1,3$-galactose (alpha-Gal).\n- **Process:** Binding of anti-alpha-Gal immunoglobulin to the alpha-Gal epitope on the endothelial surface.\n- **Model:** The law of mass action is assumed to govern the interaction.\n- **Definitions and Constants:**\n    - Association rate constant: $k_{\\text{on}} = 10^{5}\\,\\text{M}^{-1}\\text{s}^{-1}$.\n    - Dissociation rate constant: $k_{\\text{off}} = 10^{-3}\\,\\text{s}^{-1}$.\n    - Equilibrium dissociation constant, $K_D$, is defined as the ratio of free reactants to the bound complex under equilibrium conditions.\n- **Tasks:**\n    1. Compute the value of $K_D$ in molar ($\\text{M}$).\n    2. Provide qualitative reasoning on whether these kinetics are consistent with rapid complement activation.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, describing a key mechanism of hyperacute rejection in xenotransplantation—the binding of pre-existing human antibodies to porcine antigens. The law of mass action is the standard framework for analyzing such receptor-ligand interactions. The provided values for the rate constants are biochemically realistic for antibody-antigen binding. The definition of $K_D$ is consistent with standard biochemical conventions. The problem is well-posed, providing all necessary information for the calculation, and is stated in clear, objective language. No scientific, logical, or formal flaws are detected.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will be provided.\n\nThe binding of an antibody ($A$) to a surface epitope ($E$) to form a complex ($C$) can be represented by the reversible reaction:\n$$\nA + E \\underset{k_{\\text{off}}}{\\stackrel{k_{\\text{on}}}{\\rightleftharpoons}} C\n$$\nAccording to the law of mass action, the rate of formation of the complex (the forward reaction) is proportional to the concentrations of the free reactants:\n$$\n\\text{Rate}_{\\text{on}} = k_{\\text{on}} [A] [E]\n$$\nHere, $k_{\\text{on}}$ is the second-order association rate constant. The rate of dissociation of the complex (the reverse reaction) is proportional to the concentration of the complex:\n$$\n\\text{Rate}_{\\text{off}} = k_{\\text{off}} [C]\n$$\nwhere $k_{\\text{off}}$ is the first-order dissociation rate constant.\n\nAt equilibrium, the rate of formation equals the rate of dissociation:\n$$\n\\text{Rate}_{\\text{on}} = \\text{Rate}_{\\text{off}}\n$$\n$$\nk_{\\text{on}} [A]_{\\text{eq}} [E]_{\\text{eq}} = k_{\\text{off}} [C]_{\\text{eq}}\n$$\nThe problem states that the equilibrium dissociation constant, $K_D$, is defined as the ratio of the product of free reactant concentrations to the concentration of the bound complex at equilibrium. This is formally written as:\n$$\nK_D = \\frac{[A]_{\\text{eq}} [E]_{\\text{eq}}}{[C]_{\\text{eq}}}\n$$\nBy rearranging the equilibrium condition from the kinetic equations, we can express this ratio in terms of the rate constants:\n$$\n\\frac{[A]_{\\text{eq}} [E]_{\\text{eq}}}{[C]_{\\text{eq}}} = \\frac{k_{\\text{off}}}{k_{\\text{on}}}\n$$\nTherefore, the equilibrium dissociation constant is given by the ratio of the dissociation rate constant to the association rate constant:\n$$\nK_D = \\frac{k_{\\text{off}}}{k_{\\text{on}}}\n$$\nWe are given the values $k_{\\text{on}} = 10^{5}\\,\\text{M}^{-1}\\text{s}^{-1}$ and $k_{\\text{off}} = 10^{-3}\\,\\text{s}^{-1}$. Substituting these values into the expression for $K_D$:\n$$\nK_D = \\frac{10^{-3}\\,\\text{s}^{-1}}{10^{5}\\,\\text{M}^{-1}\\text{s}^{-1}} = 10^{-8}\\,\\text{M}\n$$\nThe resulting unit is Molar ($\\text{M}$), as required. This value, $10^{-8}\\,\\text{M}$, corresponds to $10$ nanomolar ($10\\,\\text{nM}$), which indicates a high-affinity interaction.\n\nFor the qualitative analysis, we must consider the implications of this $K_D$ value for the activation of the classical complement pathway (CP).\n1.  **Affinity and Occupancy:** The $K_D$ of $10^{-8}\\,\\text{M}$ signifies a strong binding affinity between the human anti-alpha-Gal antibodies and the porcine alpha-Gal epitopes. The concentration of natural anti-alpha-Gal IgG in human serum is typically in the range of $10^{-7}$ to $10^{-6}\\,\\text{M}$. This concentration is significantly higher than the calculated $K_D$. The fractional occupancy ($\\theta$) of epitopes is given by $\\theta = \\frac{[A]}{K_D + [A]}$. Since the antibody concentration $[A]$ is much greater than $K_D$, the fractional occupancy $\\theta$ will approach $1$. This means that upon exposure of porcine endothelium to human serum, a very high density of alpha-Gal epitopes will be rapidly and near-completely saturated with antibodies.\n\n2.  **Complement Activation Mechanism:** The classical pathway of complement is initiated by the binding of the C1q molecule to the Fc regions of antigen-bound antibodies. For IgG, the most common class of anti-alpha-Gal antibodies, the activation of C1q requires binding to at least two IgG Fc domains in close proximity (typically within $10$-$40$ nanometers).\n\n3.  **Synthesis:** The high expression level of alpha-Gal on porcine endothelial cells, combined with the high affinity (low $K_D$) and high concentration of circulating natural antibodies, ensures the rapid formation of a high-density array of antibody-epitope complexes on the cell surface. This dense opsonization makes it statistically highly probable that multiple IgG molecules will be bound close enough to one another to create the necessary binding sites for C1q.\n\nFurthermore, the kinetics themselves are telling. The high association rate constant ($k_{\\text{on}}=10^{5}\\,\\text{M}^{-1}\\text{s}^{-1}$) implies that binding occurs very quickly upon exposure. The low dissociation rate constant ($k_{\\text{off}}=10^{-3}\\,\\text{s}^{-1}$) corresponds to a long half-life of the complex ($t_{1/2} = \\ln(2)/k_{\\text{off}} \\approx 693\\,\\text{s}$), meaning the antibodies remain bound for an extended period. This provides a stable, decorated surface for the C1q molecule to locate its targets and initiate the complement cascade, which proceeds very rapidly once triggered.\n\nIn conclusion, the calculated high-affinity binding, combined with rapid association, slow dissociation, and the high physiological concentrations of both antibody and antigen, creates the ideal platform for multivalent C1q binding. This leads to robust and immediate activation of the classical complement pathway, which is fully consistent with the observed phenomenon of hyperacute rejection in xenotransplantation.", "answer": "$$\\boxed{10^{-8}}$$", "id": "5076068"}, {"introduction": "Successfully overcoming immune rejection reveals deeper physiological incompatibilities, such as mismatches in the coagulation system that can lead to thrombosis or hemorrhage. Modern xenotransplantation relies on genetic engineering to bridge these molecular divides, for instance, by expressing human regulatory proteins in the donor organ. This practice [@problem_id:5076023] places you in the role of a translational scientist, tasking you with using enzyme kinetic principles to calculate the precise surface density of human thrombomodulin needed on porcine cells to restore normal anticoagulant function, demonstrating how quantitative biology guides the design of effective genetic modifications.", "problem": "A central hemostatic barrier in xenotransplantation is the mismatch between porcine endothelial regulatory proteins and human coagulation enzymes. Thrombomodulin (TM) on the endothelial surface binds human thrombin to catalyze activation of Protein C (PC), thereby downregulating coagulation. In a biochemical regime where the thrombin concentration is small compared to the Michaelis constant, the steady-state rate of PC activation per unit area can be derived from the law of mass action and the quasi-steady-state approximation for enzyme kinetics. Specifically, if the thrombomodulin–thrombin complex acts as the catalyst, then the rate of PC activation per unit area is proportional to the catalytic efficiency, defined as the ratio of the catalytic rate constant to the Michaelis constant, $k_{\\mathrm{cat}}/K_{m}$, times the surface density of TM and the local thrombin concentration. When multiple TM species are present (e.g., human TM and porcine TM), their contributions to the overall rate are additive at fixed thrombin concentration.\n\nConsider the following scientifically plausible scenario. On human endothelium, the surface density of TM is $1.80 \\times 10^{3}$ molecules per square micrometer. On genetically modified porcine endothelium, porcine TM (pTM) is expressed at $2.00 \\times 10^{3}$ molecules per square micrometer. With human thrombin, pTM exhibits a catalytic efficiency $0.20$ times that of human TM (hTM), while hTM has efficiency $1.00$ relative to itself. Assume the thrombin concentration is identical in the human and porcine settings and is sufficiently low that the linear dependence on $k_{\\mathrm{cat}}/K_{m}$, TM surface density, and thrombin concentration holds.\n\nDetermine the required endothelial expression level of human thrombomodulin on the porcine endothelium, in molecules per square micrometer, so that the total PC activation rate on the porcine endothelium equals that of human endothelium. Round your answer to three significant figures. Express your final answer in molecules per square micrometer.", "solution": "The problem is validated as scientifically grounded, well-posed, and objective. It is based on standard principles of enzyme kinetics applied to a relevant problem in xenotransplantation. All necessary data are provided, and the problem structure allows for a unique, meaningful solution.\n\nLet $v$ be the rate of Protein C (PC) activation per unit area. According to the problem statement, in the regime of low thrombin concentration, this rate is proportional to the catalytic efficiency of the thrombomodulin (TM), the surface density of TM, and the local thrombin concentration. We can write this relationship as:\n$$v = C \\cdot \\mathcal{E} \\cdot \\sigma \\cdot [\\text{IIa}]$$\nwhere $C$ is a proportionality constant, $\\mathcal{E}$ is the catalytic efficiency defined as $k_{\\mathrm{cat}}/K_{m}$, $\\sigma$ is the surface density of TM molecules, and $[\\text{IIa}]$ is the local concentration of thrombin.\n\nFirst, let's establish the rate of PC activation on the native human endothelium, $v_{\\text{human}}$. This surface contains only human TM (hTM).\nThe given variables are:\n- Surface density of hTM on human endothelium: $\\sigma_{\\text{hTM, human}} = 1.80 \\times 10^{3} \\, \\text{molecules}/\\mu\\text{m}^2$.\nLet the catalytic efficiency of hTM be denoted by $\\mathcal{E}_{\\text{hTM}}$.\nThe rate on the human endothelium is therefore:\n$$v_{\\text{human}} = C \\cdot \\mathcal{E}_{\\text{hTM}} \\cdot \\sigma_{\\text{hTM, human}} \\cdot [\\text{IIa}]$$\n\nNext, let's establish the rate of PC activation on the genetically modified porcine endothelium, $v_{\\text{porcine}}$. This surface contains both native porcine TM (pTM) and the added transgenic hTM. The problem states that when multiple TM species are present, their contributions to the overall rate are additive.\nThe given variables for the porcine surface are:\n- Surface density of pTM on porcine endothelium: $\\sigma_{\\text{pTM, porcine}} = 2.00 \\times 10^{3} \\, \\text{molecules}/\\mu\\text{m}^2$.\n- The required surface density of hTM on the porcine endothelium, which we need to determine: $\\sigma_{\\text{hTM, porcine}}$.\n- The catalytic efficiency of pTM, $\\mathcal{E}_{\\text{pTM}}$, is $0.20$ times that of hTM. We can write this as $\\mathcal{E}_{\\text{pTM}} = 0.20 \\cdot \\mathcal{E}_{\\text{hTM}}$.\n\nThe total rate on the porcine endothelium is the sum of the rates from both pTM and the added hTM:\n$$v_{\\text{porcine}} = v_{\\text{pTM}} + v_{\\text{hTM}}$$\n$$v_{\\text{porcine}} = (C \\cdot \\mathcal{E}_{\\text{pTM}} \\cdot \\sigma_{\\text{pTM, porcine}} \\cdot [\\text{IIa}]) + (C \\cdot \\mathcal{E}_{\\text{hTM}} \\cdot \\sigma_{\\text{hTM, porcine}} \\cdot [\\text{IIa}])$$\nWe can factor out the common terms $C$ and $[\\text{IIa}]$:\n$$v_{\\text{porcine}} = C \\cdot [\\text{IIa}] \\cdot (\\mathcal{E}_{\\text{pTM}} \\cdot \\sigma_{\\text{pTM, porcine}} + \\mathcal{E}_{\\text{hTM}} \\cdot \\sigma_{\\text{hTM, porcine}})$$\n\nThe problem requires us to find the value of $\\sigma_{\\text{hTM, porcine}}$ such that the total PC activation rate on the porcine endothelium equals that of the human endothelium.\n$$v_{\\text{porcine}} = v_{\\text{human}}$$\nSubstituting the expressions for the rates:\n$$C \\cdot [\\text{IIa}] \\cdot (\\mathcal{E}_{\\text{pTM}} \\cdot \\sigma_{\\text{pTM, porcine}} + \\mathcal{E}_{\\text{hTM}} \\cdot \\sigma_{\\text{hTM, porcine}}) = C \\cdot \\mathcal{E}_{\\text{hTM}} \\cdot \\sigma_{\\text{hTM, human}} \\cdot [\\text{IIa}]$$\nThe thrombin concentration $[\\text{IIa}]$ and the proportionality constant $C$ are non-zero and appear on both sides of the equation, so they can be canceled:\n$$\\mathcal{E}_{\\text{pTM}} \\cdot \\sigma_{\\text{pTM, porcine}} + \\mathcal{E}_{\\text{hTM}} \\cdot \\sigma_{\\text{hTM, porcine}} = \\mathcal{E}_{\\text{hTM}} \\cdot \\sigma_{\\text{hTM, human}}$$\nNow, substitute the relationship $\\mathcal{E}_{\\text{pTM}} = 0.20 \\cdot \\mathcal{E}_{\\text{hTM}}$ into the equation:\n$$(0.20 \\cdot \\mathcal{E}_{\\text{hTM}}) \\cdot \\sigma_{\\text{pTM, porcine}} + \\mathcal{E}_{\\text{hTM}} \\cdot \\sigma_{\\text{hTM, porcine}} = \\mathcal{E}_{\\text{hTM}} \\cdot \\sigma_{\\text{hTM, human}}$$\nThe term $\\mathcal{E}_{\\text{hTM}}$ is a common factor in every term and is non-zero, so it can be divided out:\n$$0.20 \\cdot \\sigma_{\\text{pTM, porcine}} + \\sigma_{\\text{hTM, porcine}} = \\sigma_{\\text{hTM, human}}$$\nWe are solving for $\\sigma_{\\text{hTM, porcine}}$. Rearranging the equation:\n$$\\sigma_{\\text{hTM, porcine}} = \\sigma_{\\text{hTM, human}} - 0.20 \\cdot \\sigma_{\\text{pTM, porcine}}$$\nNow we substitute the given numerical values:\n$$\\sigma_{\\text{hTM, porcine}} = (1.80 \\times 10^{3}) - 0.20 \\cdot (2.00 \\times 10^{3})$$\n$$\\sigma_{\\text{hTM, porcine}} = (1.80 \\times 10^{3}) - (0.400 \\times 10^{3})$$\n$$\\sigma_{\\text{hTM, porcine}} = (1.80 - 0.400) \\times 10^{3}$$\n$$\\sigma_{\\text{hTM, porcine}} = 1.40 \\times 10^{3}$$\nThe resulting unit is molecules per square micrometer. The value $1.40 \\times 10^3$ is already expressed with three significant figures, as requested.", "answer": "$$\\boxed{1.40 \\times 10^{3}}$$", "id": "5076023"}, {"introduction": "The ultimate measure of a xenotransplant's success lies in its long-term performance within a patient, an outcome that is often complex to assess. In clinical trials, events like graft failure and patient death are \"competing risks,\" and analyzing them requires specialized statistical methods to avoid biased conclusions. This final exercise [@problem_id:5076064] delves into the fundamentals of survival analysis, guiding you to derive the relationship between event-free survival, $S(t)$, and the cumulative incidence of competing endpoints, $F_k(t)$. By applying this framework, you will learn to correctly interpret clinical trial data and quantify the true benefit of a xenograft in a real-world scenario.", "problem": "A first-in-human clinical study evaluates genetically engineered porcine kidney xenotransplantation in immunologically high-risk adult recipients. Let $T$ denote the time from transplant to the first occurring endpoint among two competing events: (i) death prior to graft failure, and (ii) graft failure prior to death. Assume there are no other causes and no loss to follow-up through $t=12$ months. Let $h_1(t)$ and $h_2(t)$ be the cause-specific hazard functions for death-prior-to-failure and graft-failure-prior-to-death, respectively. Let $S(t)$ denote the event-free survival function, that is, the probability of being alive with a functioning graft at time $t$, and let $F_1(t)$ and $F_2(t)$ denote the cumulative incidence functions (CIF) for the two causes.\n\nStarting only from the core definitions of survival analysis and competing risks—namely, that for each cause $k \\in \\{1,2\\}$, the cause-specific hazard is $h_k(t) = \\lim_{\\Delta t \\to 0^{+}} \\frac{\\mathbb{P}(t \\le T < t+\\Delta t, \\text{cause}=k \\mid T \\ge t)}{\\Delta t}$, the overall hazard is $h(t)=h_1(t)+h_2(t)$, the event-free survival is $S(t)=\\exp\\!\\left(-\\int_{0}^{t} h(u)\\,du\\right)$, and the cumulative incidence for cause $k$ is $F_k(t)=\\int_{0}^{t} S(u)\\,h_k(u)\\,du$—derive an explicit expression linking $S(t)$ to $F_1(t)$ and $F_2(t)$ under the stated assumptions. Then, using this relationship and the empirical findings that by $t=12$ months the cumulative incidence of death-prior-to-failure is $F_1(12)=0.1$ and the cumulative incidence of graft-failure-prior-to-death is $F_2(12)=0.2$, compute the $12$-month graft survival $S(12)$, defined as the probability of being alive with a functioning graft at $12$ months. Express the final probability as a decimal fraction. No rounding is required.", "solution": "The problem statement is subjected to validation.\n\n### Step 1: Extract Givens\n-   $T$: time from transplant to the first occurring endpoint.\n-   Competing events: (i) death prior to graft failure (cause $k=1$), and (ii) graft failure prior to death (cause $k=2$).\n-   Assumptions: No other causes; no loss to follow-up through $t=12$ months.\n-   $h_k(t)$: cause-specific hazard function for cause $k \\in \\{1,2\\}$. Defined as $h_k(t) = \\lim_{\\Delta t \\to 0^{+}} \\frac{\\mathbb{P}(t \\le T < t+\\Delta t, \\text{cause}=k \\mid T \\ge t)}{\\Delta t}$.\n-   $h(t)$: overall hazard function, $h(t)=h_1(t)+h_2(t)$.\n-   $S(t)$: event-free survival function, the probability of being alive with a functioning graft at time $t$. Defined as $S(t)=\\exp\\left(-\\int_{0}^{t} h(u)\\,du\\right)$.\n-   $F_k(t)$: cumulative incidence function (CIF) for cause $k$. Defined as $F_k(t)=\\int_{0}^{t} S(u)\\,h_k(u)\\,du$.\n-   Empirical data at $t=12$ months: $F_1(12)=0.1$ and $F_2(12)=0.2$.\n-   Objective 1: Derive an explicit expression linking $S(t)$ to $F_1(t)$ and $F_2(t)$.\n-   Objective 2: Compute $S(12)$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, rooted in the standard mathematical theory of competing risks in survival analysis, a core topic in biostatistics and translational medicine. The scenario of a xenotransplantation clinical trial is realistic. The definitions provided for the hazard function, survival function, and cumulative incidence function are standard and correct. The problem is well-posed, self-contained, and provides all necessary information to derive the requested relationship and compute the final value. The language is objective and precise. There are no contradictions, ambiguities, or factual unsoundness.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A solution will be provided.\n\nThe first objective is to derive an explicit expression linking the event-free survival function, $S(t)$, to the cumulative incidence functions, $F_1(t)$ and $F_2(t)$. We start from the definitions provided.\n\nThe cumulative incidence function for cause $k$ is given by:\n$$F_k(t) = \\int_{0}^{t} S(u)\\,h_k(u)\\,du$$\nThe problem considers two competing events, corresponding to $k=1$ and $k=2$. The total probability of failure from either cause by time $t$ is the sum of their individual cumulative incidence functions, as the event types are mutually exclusive.\nLet's sum the CIFs for the two causes:\n$$F_1(t) + F_2(t) = \\int_{0}^{t} S(u)\\,h_1(u)\\,du + \\int_{0}^{t} S(u)\\,h_2(u)\\,du$$\nBy the linearity property of integration, we can combine the two integrals:\n$$F_1(t) + F_2(t) = \\int_{0}^{t} S(u) \\left( h_1(u) + h_2(u) \\right) du$$\nThe problem defines the overall hazard function $h(t)$ as the sum of the cause-specific hazard functions: $h(t) = h_1(t) + h_2(t)$. Substituting this into the equation gives:\n$$F_1(t) + F_2(t) = \\int_{0}^{t} S(u)\\,h(u)\\,du$$\nNow, we must relate this integral to the event-free survival function $S(t)$. We are given the definition of $S(t)$ in terms of the overall cumulative hazard function, $H(t) = \\int_{0}^{t} h(u)\\,du$:\n$$S(t) = \\exp\\left(-\\int_{0}^{t} h(u)\\,du\\right) = \\exp(-H(t))$$\nFrom the Fundamental Theorem of Calculus, the derivative of the cumulative hazard is the hazard function: $\\frac{d}{dt}H(t) = h(t)$. We can use this to solve the integral $\\int_{0}^{t} S(u)\\,h(u)\\,du$. Let's rewrite the integrand using $H(u)$:\n$$\\int_{0}^{t} S(u)\\,h(u)\\,du = \\int_{0}^{t} \\exp(-H(u))\\,h(u)\\,du$$\nWe can solve this integral by substitution. Let $v = H(u)$. Then the differential is $dv = H'(u)\\,du = h(u)\\,du$. We must also change the limits of integration. When $u=0$, the lower limit becomes $v = H(0) = \\int_{0}^{0} h(x)\\,dx = 0$. When $u=t$, the upper limit becomes $v=H(t)$. The integral transforms to:\n$$\\int_{0}^{H(t)} \\exp(-v)\\,dv$$\nThe antiderivative of $\\exp(-v)$ with respect to $v$ is $-\\exp(-v)$. Evaluating the definite integral gives:\n$$\\left[ -\\exp(-v) \\right]_{0}^{H(t)} = -\\exp(-H(t)) - (-\\exp(-0)) = -\\exp(-H(t)) + 1$$\nRecalling that $S(t) = \\exp(-H(t))$, we can substitute this back into the expression:\n$$1 - S(t)$$\nTherefore, we have established the relationship:\n$$F_1(t) + F_2(t) = 1 - S(t)$$\nThis is the required explicit expression. This identity states that the probability of having an event of any type by time $t$ is equal to $1$ minus the probability of being event-free at time $t$, which is logically consistent under the assumption that there are no other causes.\nRearranging this formula to solve for $S(t)$ yields:\n$$S(t) = 1 - F_1(t) - F_2(t)$$\nThe second objective is to use this relationship to compute the $12$-month event-free survival, $S(12)$. We are given the empirical values for the cumulative incidence functions at $t=12$ months:\n$$F_1(12) = 0.1$$\n$$F_2(12) = 0.2$$\nSubstituting these values into our derived expression for $S(t)$ at $t=12$:\n$$S(12) = 1 - F_1(12) - F_2(12)$$\n$$S(12) = 1 - 0.1 - 0.2$$\n$$S(12) = 1 - 0.3$$\n$$S(12) = 0.7$$\nThe $12$-month graft survival, defined as the probability of being alive with a functioning graft at $12$ months, is $0.7$.", "answer": "$$\n\\boxed{0.7}\n$$", "id": "5076064"}]}